CeriBell (NASDAQ:CBLL) Releases Earnings Results, Beats Expectations By $0.06 EPS

CeriBell (NASDAQ:CBLL) released its earnings results on Tuesday. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06, Zacks reports. CeriBell had a negative net margin of 63.83% and a negative return on equity of 48.42%. CeriBell updated its FY 2025 guidance to EPS.

CeriBell Stock Down 3.7%

CBLL stock traded down $0.42 during trading on Tuesday, hitting $10.92. 347,488 shares of the stock traded hands, compared to its average volume of 286,289. CeriBell has a 1 year low of $10.01 and a 1 year high of $32.75. The firm’s 50 day moving average is $12.08 and its two-hundred day moving average is $14.65. The stock has a market cap of $400.33 million and a price-to-earnings ratio of -3.65. The company has a debt-to-equity ratio of 0.11, a current ratio of 13.31 and a quick ratio of 12.91.

Insider Buying and Selling

In related news, CTO Raymond Woo sold 11,112 shares of the stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $12.54, for a total transaction of $139,344.48. Following the sale, the chief technology officer directly owned 167,704 shares of the company’s stock, valued at approximately $2,103,008.16. This represents a 6.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 20.10% of the company’s stock.

Institutional Trading of CeriBell

Several institutional investors have recently bought and sold shares of CBLL. JPMorgan Chase & Co. grew its position in CeriBell by 6,424.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after purchasing an additional 374,179 shares during the last quarter. Rhumbline Advisers grew its position in CeriBell by 109.9% during the 2nd quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after purchasing an additional 17,177 shares during the last quarter. New York State Common Retirement Fund grew its position in CeriBell by 148.6% during the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock valued at $163,000 after purchasing an additional 5,200 shares during the last quarter. Quantbot Technologies LP boosted its holdings in shares of CeriBell by 70.3% during the 2nd quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock valued at $290,000 after acquiring an additional 6,401 shares during the last quarter. Finally, Invesco Ltd. purchased a new stake in shares of CeriBell during the 2nd quarter valued at about $197,000.

Analyst Ratings Changes

A number of research firms have recently weighed in on CBLL. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. Raymond James Financial began coverage on shares of CeriBell in a research report on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $30.50.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.